Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
Qinghua XuCaicun Zhou

Abstract

The aim of the current study was to investigate whether consolidative local ablative therapy (LAT) can improve the survival of patients with stage IV EGFR-mutant NSCLC who have oligometastatic disease treated with first-line EGFR-tyrosine kinase inhibitor (TKI) therapy. Patients with stage IV EGFR-mutant NSCLC and no more than five metastases within 2 months of diagnosis were identified. All patients were treated with first-line EGFR-TKIs. Consolidative LAT included radiotherapy, surgery, or both. Overall survival (OS) and progression-free survival (PFS) were estimated by Kaplan-Meier curves. From October 2010 to May 2016, 145 patients were enrolled, including 51 (35.2%) who received consolidative LAT to all oligometastatic sites (all-LAT group), 55 (37.9%) who received consolidative LAT to either primary tumor or oligometastatic sites (part-LAT group), and 39 (26.9%) who did not receive any consolidative LAT (non-LAT group). The median PFS in all-LAT, part-LAT, and non-LAT groups were 20.6, 15.6, and 13.9 months, respectively (p < 0.001). The median OS in all-LAT, part-LAT, and non-LAT groups were 40.9, 34.1, and 30.8 months, respectively (p < 0.001). The difference was statistically significant between the all-LAT group and p...Continue Reading

Citations

May 9, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel R GomezJohn V Heymach
Oct 9, 2019·Radiation Oncology Journal·Yang-Gun Suh, Jaeho Cho
Dec 12, 2019·The British Journal of Radiology·Marta ScorsettiArmando Santoro
Sep 21, 2019·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Jean PalussièreFrançois Chomy
Jul 15, 2020·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·T EnomotoS Atagi
May 6, 2020·Radiation Oncology·Rosario MazzolaFilippo Alongi
Dec 5, 2019·World Journal of Clinical Oncology·Felipe CouñagoElia Del Cerro
Dec 10, 2019·Journal of Cancer Research and Clinical Oncology·Wang Li, Hong Yu
Aug 24, 2020·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·P-A LaurentJ Doyen
Jan 15, 2020·Deutsches Ärzteblatt International·Jan HaussmannWilfried Budach
May 11, 2020·The Journal of Thoracic and Cardiovascular Surgery·Isabelle Opitz
Apr 26, 2020·The Journal of Thoracic and Cardiovascular Surgery·Kyle G MitchellUNKNOWN MD Anderson Cancer Center Oligometastatic Lung Cancer Working Group
Apr 29, 2020·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Lei Deng, Haiying Cheng
Aug 30, 2021·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Nicholas J ThomasCaroline E McCoach
May 9, 2021·The Annals of Thoracic Surgery·Bor-Shiuan ShyrYuh-Min Chen
Sep 29, 2019·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Sanjay Popat
Dec 28, 2021·Journal of Radiation Research·Qingren LinYuezhen Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.